دورية أكاديمية
Endocrine side effects of immune checkpoint inhibitors.
| العنوان: | Endocrine side effects of immune checkpoint inhibitors. |
|---|---|
| المؤلفون: | Cardona Z; Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Sosman JA; Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Chandra S; Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Huang W; Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. |
| المصدر: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2023 May 11; Vol. 14, pp. 1157805. Date of Electronic Publication: 2023 May 11 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Endocrine System Diseases*/chemically induced , Endocrine System Diseases*/therapy , Adrenal Gland Diseases* , Neoplasms*/drug therapy , Drug-Related Side Effects and Adverse Reactions*, Humans ; Immune Checkpoint Inhibitors/adverse effects ; Endocrine System |
| مستخلص: | Immune checkpoint inhibitors (ICIs) have increasingly been the mainstay of treatment for numerous malignancies. However, due to their association with autoimmunity, ICIs have resulted in a variety of side effects that involve multiple organs including the endocrine system. In this review article, we describe our current understanding of the autoimmune endocrinopathies as a result of the use of ICIs. We will review the epidemiology, pathophysiology, clinical presentation, diagnosis, and management of the most commonly encountered endocrinopathies, including thyroiditis, hypophysitis, Type 1 diabetes, adrenalitis, and central diabetes insipidus. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Cardona, Sosman, Chandra and Huang.) |
| References: | J Clin Endocrinol Metab. 2018 Sep 1;103(9):3144-3154. (PMID: 29955867) Clin Exp Immunol. 2020 May;200(2):131-140. (PMID: 32027018) N Engl J Med. 2022 Jan 6;386(1):24-34. (PMID: 34986285) Pituitary. 2022 Feb;25(1):152-158. (PMID: 34518996) J Immunother Cancer. 2021 May;9(5):. (PMID: 34011534) Diabetes Care. 2019 Sep;42(9):e153-e154. (PMID: 31308021) Eur J Endocrinol. 2019 Sep 1;181(3):R107-R118. (PMID: 31311002) J Diabetes Investig. 2020 Jul;11(4):1006-1009. (PMID: 31926048) J Endocr Soc. 2018 Feb 06;2(3):241-251. (PMID: 29600292) Case Rep Endocrinol. 2019 Oct 17;2019:2314032. (PMID: 31772785) J Clin Endocrinol Metab. 2018 Feb 1;103(2):365-369. (PMID: 29220526) ESMO Open. 2020 Nov;5(6):e001079. (PMID: 33246931) J Clin Endocrinol Metab. 2019 Feb 1;104(2):550-556. (PMID: 30252069) Nature. 2017 May 25;545(7655):495-499. (PMID: 28514441) Endocrinol Metab Clin North Am. 2009 Jun;38(2):437-45, x. (PMID: 19328421) Clin Gastroenterol Hepatol. 2020 May;18(6):1393-1403.e1. (PMID: 32007539) Lancet Oncol. 2021 Feb;22(2):198-211. (PMID: 33476593) Endocrinol Diabetes Metab Case Rep. 2021 Jan 27;2021:. (PMID: 33522491) Cancers (Basel). 2021 Mar 15;13(6):. (PMID: 33804050) Endocrinol Diabetes Metab Case Rep. 2018 Feb 28;2018:. (PMID: 29511565) J Clin Endocrinol Metab. 1990 Sep;71(3):661-9. (PMID: 2168432) Case Rep Oncol Med. 2019 Nov 4;2019:8781347. (PMID: 31781446) Nat Med. 2014 Dec;20(12):1410-1416. (PMID: 25329329) J Immunother Cancer. 2020 Jun;8(1):. (PMID: 32601079) J Endocrinol Invest. 2021 Sep;44(9):1927-1933. (PMID: 33576954) J Immunother Cancer. 2020 Sep;8(2):. (PMID: 32929051) BMC Endocr Disord. 2019 Dec 23;19(1):144. (PMID: 31870373) J Natl Compr Canc Netw. 2014 Aug;12(8):1077-81. (PMID: 25099440) Int Immunopharmacol. 2020 Jun;83:106427. (PMID: 32244049) Thyroid. 2020 Feb;30(2):177-184. (PMID: 31813343) Endocr Connect. 2020 Oct;9(10):R207-R228. (PMID: 33064663) J Clin Oncol. 2018 Jun 10;36(17):1714-1768. (PMID: 29442540) J Clin Oncol. 2019 Aug 1;37(22):1927-1934. (PMID: 31206316) J Endocr Soc. 2017 Apr 28;1(6):646-649. (PMID: 29264517) Clin Endocrinol (Oxf). 2018 Feb;88(2):327-332. (PMID: 28941311) BMC Endocr Disord. 2022 Nov 22;22(1):291. (PMID: 36419114) Cancers (Basel). 2022 May 29;14(11):. (PMID: 35681667) Cancer Immunol Res. 2017 Dec;5(12):1133-1140. (PMID: 29079654) Cancer Sci. 2020 May;111(5):1468-1477. (PMID: 32086984) Mayo Clin Proc Innov Qual Outcomes. 2020 Nov 03;4(6):821-825. (PMID: 33367219) Clin Cancer Res. 2015 Feb 15;21(4):749-55. (PMID: 25538262) Clin Med (Lond). 2021 Mar;21(2):e212-e222. (PMID: 33762389) J Endocr Soc. 2019 Jan 08;3(2):496-503. (PMID: 30746508) Cancer Immunol Immunother. 2022 Sep;71(9):2169-2181. (PMID: 35072744) J Clin Oncol. 2018 Oct 1;36(28):2872-2878. (PMID: 30125216) Sci Rep. 2019 Dec 19;9(1):19419. (PMID: 31857638) Br J Cancer. 2020 Mar;122(6):771-777. (PMID: 32009131) Gac Med Mex. 2021;157(3):293-297. (PMID: 34667315) Cancer Immunol Res. 2019 Jul;7(7):1214-1220. (PMID: 31088848) J Clin Oncol. 2020 Nov 20;38(33):3925-3936. (PMID: 32946353) Thyroid. 2018 Oct;28(10):1243-1251. (PMID: 30132401) BMJ Case Rep. 2022 Jan 17;15(1):. (PMID: 35039353) J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. (PMID: 30865922) J Immunother Cancer. 2019 Nov 15;7(1):306. (PMID: 31730012) Diabetologia. 2022 Jul;65(7):1185-1197. (PMID: 35511238) BMJ Case Rep. 2016 Apr 18;2016:10.1136/bcr-2016-214603. (PMID: 27090545) J Clin Invest. 2007 Nov;117(11):3383-92. (PMID: 17932562) J Clin Endocrinol Metab. 2014 Nov;99(11):4078-85. (PMID: 25078147) Endocrinol Diabetes Metab Case Rep. 2016;2016:. (PMID: 27857838) Neuroradiology. 2018 Oct;60(10):995-1012. (PMID: 30097693) Int J Mol Sci. 2021 May 17;22(10):. (PMID: 34067904) Eur Thyroid J. 2022 Jun 29;11(4):. (PMID: 35622442) Oncologist. 2018 Sep;23(9):991-997. (PMID: 29853659) J Cachexia Sarcopenia Muscle. 2012 Sep;3(3):149-55. (PMID: 22528986) Am J Emerg Med. 2017 Jul;35(7):1039.e5-1039.e7. (PMID: 28363614) Lancet Oncol. 2020 Nov;21(11):1465-1477. (PMID: 32961119) Eur J Cancer. 2021 Apr;147:170-181. (PMID: 33706206) PLoS One. 2015 Oct 07;10(10):e0139867. (PMID: 26444869) Front Oncol. 2020 Dec 01;10:582394. (PMID: 33335854) Diagnostics (Basel). 2022 Aug 29;12(9):. (PMID: 36140493) J Clin Endocrinol Metab. 2018 Oct 1;103(10):3589-3592. (PMID: 30124874) Cancer Manag Res. 2020 Oct 02;12:9551-9561. (PMID: 33061641) Eur J Cancer. 2020 Aug;135:211-220. (PMID: 32599411) Ann Endocrinol (Paris). 2018 Oct;79(5):545-549. (PMID: 30126628) Nat Rev Endocrinol. 2021 Jul;17(7):389-399. (PMID: 33875857) Endocr Rev. 2005 Aug;26(5):599-614. (PMID: 15634713) Thyroid. 2012 Dec;22(12):1200-35. (PMID: 22954017) Eur Thyroid J. 2019 Jul;8(4):192-195. (PMID: 31602361) J Endocrinol Invest. 2018 Jun;41(6):625-638. (PMID: 29238906) Int J Mol Sci. 2020 Jun 22;21(12):. (PMID: 32580338) Cancers (Basel). 2020 Feb 27;12(3):. (PMID: 32120803) JAMA Oncol. 2019 Mar 1;5(3):376-383. (PMID: 30589930) Eur J Endocrinol. 2019 Sep;181(3):363-374. (PMID: 31330498) Endocr Pract. 2022 Jan;28(1):110-117. (PMID: 34610473) Endocr Rev. 2019 Feb 1;40(1):17-65. (PMID: 30184160) Lancet. 2018 Jun 16;391(10138):2449-2462. (PMID: 29916386) BMJ Case Rep. 2022 Oct 12;15(10):. (PMID: 36223974) Clin Diabetes Endocrinol. 2019 Jan 22;5:1. (PMID: 30693099) J Immunother Cancer. 2021 Feb;9(2):. (PMID: 33589529) Ann Oncol. 2022 Dec;33(12):1217-1238. (PMID: 36270461) Diabetes Care. 2019 Jul;42(7):e116-e118. (PMID: 31076419) N Engl J Med. 2017 Oct 5;377(14):1345-1356. (PMID: 28889792) Eur J Endocrinol. 2019 Mar;180(3):P1-P22. (PMID: 30540559) Genome Med. 2020 Jun 24;12(1):55. (PMID: 32580776) Cancer. 2010 Mar 15;116(6):1592-601. (PMID: 20186765) J Clin Endocrinol Metab. 2019 Nov 1;104(11):5499-5506. (PMID: 31265074) Pituitary. 2010;13(1):29-38. (PMID: 19639414) Sci Rep. 2018 May 29;8(1):8295. (PMID: 29844327) Oncotarget. 2021 Feb 02;12(3):199-208. (PMID: 33613847) J Clin Endocrinol Metab. 2010 Mar;95(3):1095-104. (PMID: 20097710) Endocrinol Diabetes Metab Case Rep. 2022 Feb 01;2022:. (PMID: 35140188) Diabetes. 2018 Aug;67(8):1471-1480. (PMID: 29937434) Nat Immunol. 2022 Sep;23(9):1365-1378. (PMID: 35999394) N Engl J Med. 2018 May 31;378(22):2078-2092. (PMID: 29658856) J Endocr Soc. 2021 Jun 01;5(8):bvab100. (PMID: 34195529) Cancer Immunol Res. 2015 May;3(5):464-9. (PMID: 25649350) Cancer Res. 2017 Nov 15;77(22):6365-6374. (PMID: 28947422) Cancer Immunol Immunother. 2017 Nov;66(11):1399-1410. (PMID: 28634815) Front Oncol. 2022 Jul 14;12:894015. (PMID: 35912205) BMC Endocr Disord. 2020 Aug 26;20(1):132. (PMID: 32847555) Front Oncol. 2022 Mar 03;12:798517. (PMID: 35311088) J Immunol. 2009 Jun 1;182(11):6659-69. (PMID: 19454660) Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):524-9. (PMID: 25548162) Front Oncol. 2022 Mar 08;12:836859. (PMID: 35350573) Thyroid. 2016 Oct;26(10):1343-1421. (PMID: 27521067) N Engl J Med. 2018 Aug 02;379(5):428-439. (PMID: 30067922) Diabetes Care. 2021 Jan;44(Suppl 1):S211-S220. (PMID: 33298426) Oncologist. 2020 Aug;25(8):696-701. (PMID: 32390168) J Clin Endocrinol Metab. 2022 Jan 1;107(1):10-28. (PMID: 34528683) Surv Ophthalmol. 2021 Nov-Dec;66(6):951-959. (PMID: 33440195) J Clin Oncol. 2019 Oct 1;37(28):2518-2527. (PMID: 31154919) Cancers (Basel). 2021 Apr 17;13(8):. (PMID: 33920721) J Clin Med. 2020 Dec 29;10(1):. (PMID: 33383673) Hum Vaccin Immunother. 2019;15(5):1111-1122. (PMID: 30888929) Immunotherapy. 2021 Oct;13(15):1255-1260. (PMID: 34424037) J Endocr Soc. 2017 Dec 13;2(1):91-95. (PMID: 29362727) BMJ Case Rep. 2019 Aug 28;12(8):. (PMID: 31466960) J Clin Endocrinol Metab. 2002 Feb;87(2):489-99. (PMID: 11836274) Arch Endocrinol Metab. 2020 Aug;64(4):483-486. (PMID: 32267349) JAMA Oncol. 2018 Feb 01;4(2):173-182. (PMID: 28973656) J Clin Endocrinol Metab. 2016 Feb;101(2):364-89. (PMID: 26760044) J Thorac Dis. 2019 May;11(5):1919-1928. (PMID: 31285885) AACE Clin Case Rep. 2020 Nov 28;7(1):23-25. (PMID: 33718603) Oncologist. 2020 Apr;25(4):290-300. (PMID: 32297436) J Med Case Rep. 2018 Jun 19;12(1):171. (PMID: 29914537) Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S8-S20. (PMID: 29299404) Eur J Cancer. 2018 Nov;104:247-249. (PMID: 30377030) Expert Rev Endocrinol Metab. 2019 Nov;14(6):381-398. (PMID: 31842671) Lancet Diabetes Endocrinol. 2013 Nov;1(3):e15. (PMID: 24622375) J Endocrinol Invest. 2022 Nov;45(11):2131-2137. (PMID: 35870109) Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. (PMID: 28881921) |
| معلومات مُعتمدة: | T32 DK007169 United States DK NIDDK NIH HHS |
| فهرسة مساهمة: | Keywords: adrenal insufficiency; adrenalitis; central diabetes insipidus; endocrine side effects; hypophysitis; immune checkpoint inhibitor (ICI); thyroiditis; type1 diabetes |
| المشرفين على المادة: | 0 (Immune Checkpoint Inhibitors) |
| تواريخ الأحداث: | Date Created: 20230530 Date Completed: 20230601 Latest Revision: 20240402 |
| رمز التحديث: | 20240402 |
| مُعرف محوري في PubMed: | PMC10210589 |
| DOI: | 10.3389/fendo.2023.1157805 |
| PMID: | 37251665 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-2392 |
|---|---|
| DOI: | 10.3389/fendo.2023.1157805 |